Although we have developed a prognostic model grounded in the identified genes and have demonstrated their prognostic significance, a finding consistently corroborated by independent datasets, the considerable heterogeneity in molecular characteristics (such as hormone receptor status, HER2 expression, and mutational profiles) and clinical outcomes across various breast cancer subtypes prompts questions regarding the model’s generalizability to all subtypes. This evidence concerns the gene NR4A1 and breast cancer.